

Press Release



Notice regarding the transfer of manufacturing and marketing approval and distribution rights for the transdermal follicle and luteinizing hormone preparation "MENOAID® COMBIPATCH"

TOKYO, June 03th, 2019 – ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo, President: Takashi Yamaguchi, hereinafter "ASKA") has announced that as of September 1st 2019, ASKA will be transferring the manufacturing and marketing approval and distribution rights for the transdermal follicle and luteinizing hormone preparation "MENOAID® COMBIPATCH" (generic name: estradiol, norethisterone acetate) to Hisamitsu Pharmaceutical Co.,Inc. (Head Office: Tosu, Saga, President: Kazuhide Nakatomi, hereinafter "Hisamitsu").

As of September 1st 2019, Hisamitsu will provide as well as collect information regarding the proper use of the above product as the manufacturer and distributor and will continue to ensure a stable supply.

【The outline of the transfer product】

Product name	MENOAID® COMBIPATCH
Active ingredients and strengths	0.62mg estradiol and 2.70mg norethisterone acetate per one patch (9cm ²)
Dosage form	White translucent and round shape transdermal patch
Indications and usage	Vasomotor symptoms (hot flashes and seating) due to menopause and ovarian failure
Dosage and administration	Generally, in adults, one patch of MENOAID® COMBIPATCH is applied to the abdomen once every 3 to 4 days (twice weekly)

[Inquiries regarding this matter]

Hisamitsu Pharmaceutical Co., Inc.

TEL: +81-3-5293-1732

ASKA Pharmaceutical Co., Ltd.

TEL: +81-3-5484-8366